Heart Disease :: Tβ4 is essential for coronary vessel development report

REGENERX BIOPHARMACEUTICALS, INC. (AMEX: RGN) reported today that a study published in the advanced online edition of the journal Nature supported and elaborated TB4’s significant effects in the damaged hearts of mice and highlighted its therapeutic potential for the treatment of heart attacks and heart failure in humans.

Dr. Anil Singhal Homeopathic Doctor | Dr. Anil Singhal's Blog | Manan - My Memoir by Dr. Anil Singhal | Boger's Legacy | Organon of Medicine | Health Newstrack